Post Profile






CAR T, immunotherapy bring new hope for multiple myeloma patients

(University of Pennsylvania School of Medicine) Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Both of these investigational approaches targeted a receptor called B-Cell Maturation Antigen (BCMA), which is highly expressed in myeloma and thus a promising target for treatment.
read more

share

Related Posts


Global CAR T Therapy Trial Shows High Rates of Durable Remission for Non-Hodgkin's Lymphoma

Health : Newswise Medical News

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah(tm) (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patie...

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remaine...

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Health : Newswise Medical News

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment wit...

Global CAR T therapy trial shows high rates of durable remission for NHL

Health : EurekAlert: Health

(University of Pennsylvania School of Medicine) In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah? (formerly known as CTL019) demonstrated long-lasting rem...

CAR T, Immunotherapy Bring New Hope for Multiple Myeloma Patients

Health : Newswise Medical News

Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therap...

Comments


Copyright © 2016 Regator, LLC